These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 8122796)

  • 21. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
    van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
    J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A complete system for identifying inhibitors of creatine kinase B.
    Towler EM; Wilson LK; Zhou YC; Ma TS; Fisher RJ
    Anal Biochem; 2000 Mar; 279(1):96-9. PubMed ID: 10683236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
    Hoog SS; Towler EM; Zhao B; Doyle ML; Debouck C; Abdel-Meguid SS
    Biochemistry; 1996 Aug; 35(32):10279-86. PubMed ID: 8756683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitor-resistant mutants of the HIV-1 aspartic protease.
    Korant BD
    Adv Exp Med Biol; 1995; 362():407-11. PubMed ID: 8540350
    [No Abstract]   [Full Text] [Related]  

  • 25. A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.
    Ast O; Jentsch KD; Schramm HJ; Hunsmann G; Lüke W; Petry H
    J Virol Methods; 1998 Mar; 71(1):77-85. PubMed ID: 9628224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of inhibitors of HIV-1 protease using an Escherichia coli cell assay.
    Büttner J; Dornmair K; Schramm HJ
    Biochem Biophys Res Commun; 1997 Apr; 233(1):36-8. PubMed ID: 9144391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rational approach in the search for potent inhibitors against HIV proteinase.
    Hui KY; Manetta JV; Gygi T; Bowdon BJ; Keith KA; Shannon WM; Lai MH
    FASEB J; 1991 Aug; 5(11):2606-10. PubMed ID: 1868985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus proteinase: now, then, what's next?
    Graves MC
    Adv Exp Med Biol; 1991; 306():395-405. PubMed ID: 1812736
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV protease assays.
    Furfine ES
    Curr Protoc Pharmacol; 2001 May; Chapter 3():Unit3.2. PubMed ID: 21971798
    [No Abstract]   [Full Text] [Related]  

  • 30. Expression of the HIV aspartic protease fused to a bacterial phenotypic marker.
    Korant BD; Rizzo CJ
    Adv Exp Med Biol; 1991; 306():429-32. PubMed ID: 1812739
    [No Abstract]   [Full Text] [Related]  

  • 31. Some aspects of the preclinical safety of drugs produced by recombinant DNA technology: Japanese government regulatory position.
    Hayakawa T
    Prog Clin Biol Res; 1987; 235():15-29. PubMed ID: 3299390
    [No Abstract]   [Full Text] [Related]  

  • 32. Screening assays for protein synthesis inhibitors.
    Hall CC; Bertasso A; Watkins JD; Georgopapadakou NH
    J Antibiot (Tokyo); 1992 Oct; 45(10):1697-9. PubMed ID: 1282123
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.
    Lescar J; Brynda J; Rezacova P; Stouracova R; Riottot MM; Chitarra V; Fabry M; Horejsi M; Sedlacek J; Bentley GA
    Protein Sci; 1999 Dec; 8(12):2686-96. PubMed ID: 10631984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A rapid and simple screening method for HIV-1 protease inhibitors using recombinant Escherichia coli.
    Kaneto R; Kojima I; Shibamoto N; Nishida H; Okamoto R; Akagawa H; Mizuno S
    J Antibiot (Tokyo); 1994 Apr; 47(4):492-5. PubMed ID: 8195050
    [No Abstract]   [Full Text] [Related]  

  • 35. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Establishment of a microbial assay for screening anti-human immunodeficiency virus type-1 protease inhibitors].
    Leng Q; Tao P; Wang L; Gao Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Apr; 21(2):140-5. PubMed ID: 12569671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A rapid screening method for biological activity of human immunodeficiency virus proteinase inhibitors by using a recombinant DNA-derived bacterial system.
    Sedlácek J; Fábry M; Horejsí M; Brynda J; Luftig RB; Majer P
    Anal Biochem; 1993 Dec; 215(2):306-9. PubMed ID: 8122796
    [No Abstract]   [Full Text] [Related]  

  • 38. Screening for HIV protease inhibitors by protection against activity-mediated cytotoxicity in Escherichia coli.
    Cheng YS; Lo KH; Hsu HH; Shao YM; Yang WB; Lin CH; Wong CH
    J Virol Methods; 2006 Oct; 137(1):82-7. PubMed ID: 16849028
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.